Non‐Allergic Urticarial Skin Reactions Associated With MOv18 IgE , a First‐In‐Class IgE Antibody Recognising Folate Receptor Alpha
Allergy · 2025-08 · 80 (8) · 2225-2239
DOI: 10.1111/all.16514 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Allergy, online erschienen am 06.03.2025. Verfasst von Chara Stavraka und 28 weiteren Autor:innen. Beteiligte Einrichtung: St. John's Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, King's College London, London, UK. Hauptthemen laut MEDLINE: Folate Receptor 1, Immunoglobulin E, Urticaria. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CSP VA, British Skin Foundation, CRUK/NIHR in England/DoH for Scotland, Wales and Northern Ireland Experimental Cancer Medicine Centre.
Abstract (Originalsprache)
Background
IgE antibodies directed against cancer antigens have demonstrated potent anti‐tumour effects in pre‐clinical studies. MOv18 IgE, the first‐in‐class IgE recognising the cancer antigen folate receptor alpha (FRα), showed preliminary signs of efficacy in a Phase I trial. Treatment was well tolerated, with the most common adverse event being transient urticarial skin reactions. We investigated immunological and allergic response parameters associated with urticarial skin reactions in MOv18 IgE‐treated patients.
Methods
Expression of target antigen, FRα, and MOv18 IgE reactivity with FRα or any component in human skin was studied by immunohistochemistry, immunofluorescence and immuno‐mass spectrometry. We conducted transcriptomic analyses in paired lesional and non‐lesional skin biopsies from a patient who developed an urticarial skin reaction. Systemic immunological markers including cytokines, β‐tryptase and basophil activation states were interrogated throughout the trial and contemporaneously with the skin reaction.
Results
Of the 24 IgE‐treated patients, 62.5% developed transient urticarial skin reactions, with onset during the first infusion, diminishing with consecutive infusions and no β‐tryptase elevation nor clinical features indicating allergic aetiology. No FRα expression or MOv18 IgE binding to human skin was identified. Lesional skin biopsies from a patient given the highest antibody dose revealed scattered eosinophils, neutrophils and mast cell degranulation, but no increased immune cell infiltration. Transcriptomic analysis indicated pro‐inflammatory, but not allergic, pathway activation. No systemic allergic or hypersensitivity mediators or basophil activation were detected.
Conclusions
Urticarial skin reactions following MOv18 IgE treatment were unlikely to result from allergic mechanisms or skin antigen recognition. The clinical presentation is consistent with infusion‐related reactions commonly observed with monoclonal antibody treatments. Trial Registration EudraCT number: 2014‐000070‐19; ClinicalTrials.gov identifier: NCT02546921, registered 11/Sept/2015
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- St. John's Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, King's College London, London, UK.
- School of Cancer & Pharmaceutical Sciences, King's College London, Guy's Hospital, London, UK.
- King's Health Partners Cancer Biobank, School of Cancer & Pharmaceutical Sciences, King's College London, Guy's Hospital, London, UK.
- Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.
- Division of Clinical Biochemistry, Laboratory Medicine Program, Toronto General Hospital, Toronto, Canada.
- Mount Sinai Hospital, Toronto, Canada.
ORCID-Profile: Chara Stavraka, Jitesh Chauhan, Silvia Crescioli, Sheila M McSweeney, Amy Pope, Cheryl Gillett, Ashley Di Meo, Ioannis Prassas, Roman Laddach, Katie Stoker, Alexandra J McCraw, Rebecca Adams, Thomas J Tull, Nabeel Naban, Zena Willsmore, Kristina V Semkova, Clive E H Grattan, John McGrath, Stephen J Till, Christopher J Corrigan, Rebecca Kristeleit, Sophia Tsoka, Eleftherios P Diamandis, Katie E Lacy, Sarah Pinder, Debra H Josephs, James Spicer, Heather J Bax, Sophia N Karagiannis
Förderung
- CSP VA
- British Skin Foundation
- CRUK/NIHR in England/DoH for Scotland, Wales and Northern Ireland Experimental Cancer Medicine Centre
- The Cancer Research UK City of London Centre
- Cancer Research UK King's Health Partners Centre at King's College London
- Cancer Research UK
- Worldwide Cancer Research
- Medical Research Council
Zitieren
APA
Stavraka, C., Chauhan, J., Crescioli, S., McSweeney, S. M., Pope, A., Gillett, C., Di Meo, A., Prassas, I., Laddach, R., Stoker, K., McCraw, A. J., Adams, R., Tull, T. J., Naban, N., Willsmore, Z., Semkova, K. V., Grattan, C. E. H., McGrath, J., Till, S. J., …, & Karagiannis, S. N. (2025). Non‐Allergic Urticarial Skin Reactions Associated With MOv18 IgE , a First‐In‐Class IgE Antibody Recognising Folate Receptor Alpha. Allergy, 80(8), 2225-2239. https://doi.org/10.1111/all.16514
Vancouver
Stavraka C, Chauhan J, Crescioli S, McSweeney SM, Pope A, Gillett C, et al. Non‐Allergic Urticarial Skin Reactions Associated With MOv18 IgE , a First‐In‐Class IgE Antibody Recognising Folate Receptor Alpha. Allergy. 2025;80(8):2225-2239. doi:10.1111/all.16514
BibTeX
@article{Stavraka2025,
author = {Stavraka, Chara and Chauhan, Jitesh and Crescioli, Silvia and McSweeney, Sheila M and Pope, Amy and Gillett, Cheryl and Di Meo, Ashley and Prassas, Ioannis and Laddach, Roman and Stoker, Katie and McCraw, Alexandra J and Adams, Rebecca and Tull, Thomas J and Naban, Nabeel and Willsmore, Zena and Semkova, Kristina V and Grattan, Clive E H and McGrath, John and Till, Stephen J and Corrigan, Christopher J and Kristeleit, Rebecca and Tsoka, Sophia and Diamandis, Eleftherios P and Lacy, Katie E and Pinder, Sarah and Josephs, Debra H and Spicer, James and Bax, Heather J and Karagiannis, Sophia N},
title = {Non‐Allergic Urticarial Skin Reactions Associated With MOv18 IgE , a First‐In‐Class IgE Antibody Recognising Folate Receptor Alpha},
journal = {Allergy},
year = {2025},
volume = {80},
number = {8},
pages = {2225--2239},
doi = {10.1111/all.16514}
}
EUVIMED